Tvardi Therapeutics (TVRD) Cash from Financing Activities (2013 - 2025)
Tvardi Therapeutics (TVRD) posted Cash from Financing Activities of $1000.0 for Q4 2025, up 100.31% sequentially from -$322000.0 in Q3 2025, and down 100.0% YoY from $27.0 million in Q4 2024.
Tvardi Therapeutics (TVRD) Cash from Financing Activities (2013 - 2025) Analysis & Trends
Tvardi Therapeutics has reported Cash from Financing Activities for 13 years, with the latest figure at $1000.0 in Q4 2025.
- Quarterly Cash from Financing Activities fell 100.0% year-over-year to $1000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $22.7 million (down 15.91% YoY) and the FY2025 annual result came in at $22.7 million, down 15.91% from the prior year.
- Cash from Financing Activities rose to $1000.0 in Q4 2025 per TVRD's latest filing, from -$322000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $45.3 million in Q4 2021 and troughed at -$1.6 million in Q1 2025.
- A 5-year average of $7.1 million and a median of $293000.0 in 2021 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities surged 165695.45% in 2023, then plunged 2200.0% in 2025.
- Over 5 years, Cash from Financing Activities stood at $45.3 million in 2021, then slumped by 99.95% to $22000.0 in 2022, then soared by 165695.45% to $36.5 million in 2023, then fell by 25.95% to $27.0 million in 2024, then tumbled by 100.0% to $1000.0 in 2025.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $1000.0, -$322000.0, and $24.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Sep 30, 2025 | -322,000.00 |
| Sep 30, 2025 | -322,000.00 |
| Jun 30, 2025 | 24.63 Mn |
| Jun 30, 2025 | 24.63 Mn |
| Mar 31, 2025 | -1.60 Mn |
| Mar 31, 2025 | -1.60 Mn |
| Dec 31, 2024 | 27.01 Mn |
| Dec 31, 2024 | 27.01 Mn |
| Sep 30, 2024 | -14,000.00 |
| Sep 30, 2024 | -14,000.00 |
| Jun 30, 2024 | 690,000.00 |
| Jun 30, 2024 | 690,000.00 |
| Mar 31, 2024 | -685,000.00 |
| Mar 31, 2024 | -685,000.00 |
| Dec 31, 2023 | 36.48 Mn |
| Dec 31, 2023 | 36.48 Mn |
| Sep 30, 2023 | 1.12 Mn |
| Sep 30, 2023 | 1.12 Mn |